Safety and Efficacy of Guidezilla Extension Catheter for the Percutaneous Treatment of Complex Coronary Lesions
Keywords:GuidezillaTM, percutaneous coronary intervention, complex coronary lesions
Background: The GuidezillaTM support extension catheter is designed to provide extra back-up support and efficient device delivery during complex percutaneous coronary interventions (PCIs), such as in treatment of severe calcification, tortuous chronic total occlusions (CTOs), and coronary anomalies. The aim of this study was to describe our initial experience with the GuidezillaTM extension catheter in the treatment of complex coronary artery lesions.
Methods: This study retrospectively analyzed data from 165 PCI cases that used the GuidezillaTM guide extension catheter between March 2015 and August 2017. We collected patient clinical characteristics, target lesion characteristics, and procedural details.
Results: Eighty-six percent of patients had complex Type C lesions, and 13.9% had Type B lesions. Lesion length ranged from 8 mm to 130 mm (≤ 20 mm, 15.4%; 20–40 mm, 35.8%; > 40 mm, 49.1%). The right coronary artery (59.2%) was the most common intervention vessel followed by the left ascending artery (30.6%) and the left circumflex artery (10.2%). CTO accounted for 38% of all lesions, followed by distortions (28%), heavy calcification (24%), proximal stent thrombosis (9%), and coronary artery origin anomalies (1%). A total of 142 patients underwent successful PCI using the GuidezillaTM extension catheter. The success rate was 86%.
Conclusion: The GuidezillaTM guide extension catheter was an effective and safe technique in the transradial treatment of complex coronary lesions. Use of the GuidezillaTM guide extension catheter can shorten the procedure time and ensure overall procedural success with a reduced complication rate in cases where adequate progress using angioplasty devices has not been achieved.
Chang YC, Fang HY, Chen TH, Wu CJ. 2013. Left main coronary artery bidirectional dissection caused by ejection of Guideliner catheter from the guiding catheter. Catheter Cardiovasc Interv 82:E215–20.
Cox N, Resnic FS, Popma JJ, Simon DI, Eisenhauer AC, Rogers C. 2004. Comparison of the risk of vascular complications associated with femoral and radial access coronary catheterization procedures in obese versus nonobese patients. Am J Cardiol 94:1174-7.
Cuneo A, Tebbe U. 2008. The management of chronic total coronary occlusions. Minerva Cardioangiol 56:527-41.
Di MC, Ramasami N. 2008. Techniques to enhance guide catheter support. Catheter Cardiovasc Interv 72:505-12.
Dursun H, Taştan A, Tanrıverdi Z, Özel E, Kaya D. 2016. GuideLiner catheter application in complex coronary lesions: experience of two centers. Anatol J Cardiol 16:333-9.
Garcíablas S, Núñez J, Mainar L, et al. 2015. Usefulness and Safety of a Guide Catheter Extension System for the Percutaneous Treatment of Complex Coronary Lesions by a Transradial Approach. Med Princ Pract 24:171-7.
Hildick-Smith DJ, Walsh JT, Lowe MD, Petch MC. 2010. Coronary angiography in the fully anticoagulated patient: The transradial route is successful and safe. Catheter Cardiovasc Interv 58:8-10.
Hou L, Wei YD, Li WM, Xu YW. 2010. Comparative study on transradial versus transfemoral approach for primary percutaneous coronary intervention in Chinese patients with acute myocardial infarction. Saudi Med J 31:158-62.
Hynes B, Dollard J, Murphy G, et al. 2011. Enhancing back-up support during difficult coronary stent delivery: single-center case series of experience with the Heartrail II catheter. J Invasive Cardiol 23:43-6.
Papayannis AC, Michael TT, Brilakis ES. 2012. Challenges associated with use of the GuideLiner catheter in percutaneous coronary interventions. J Invasive Cardiol 24:370-1.
Ramanathan PK, Redfern R. 2013. Use of guideliner catheter for anomalous right coronary artery angiography and intervention. J Invasive Cardiol 25:E20.
Roth C, Berger R, Scherzer S, et al. 2016. Comparison of magnetic wire navigation with the conventional wire technique for percutaneous coronary intervention of chronic total occlusions: a randomised, controlled study. Heart Vessels 31:1266-76.
Saeed B, Banerjee S, Brilakis ES. 2008. Percutaneous coronary intervention in tortuous coronary arteries: associated complications and strategies to improve success. J Interv Cardiol 21:504-11.
Tunuguntla A, Daneault B, Kirtane AJ. 2012. Novel use of the guideLiner catheter to minimize contrast use during PCI in a patient with chronic kidney disease. Catheter Cardiovasc Interv 80:453-5.
Waggoner T, Desai H, Sanghvi K. 2015. A unique complication of the GuideZilla guide extension support catheter and the risk of stent stripping in interventional & endovascular interventions. Indian Heart J 67:381-4.
Waterbury TM, Sorajja P, Bell MR, et al. 2016. Experience and complications associated with use of guide extension catheters in percutaneous coronary intervention. Catheter Cardiovasc Interv 88:1057-65.
Yamane M. 2012. Current percutaneous recanalization of coronary chronic total occlusion. Rev Esp Cardiol (Engl Ed) 65:265-77.
Yew KL, Kang Z. 2015. Guidezilla guide extension catheter facilitated the delivery of long and bulky In. Pact Falcon drug-coated balloon for the treatment of chronic total occlusion lesion. Int J Cardiol 201:220-1.
Yew KL. 2016. Guidezilla guide extension catheter enhances the delivery of bioresorbable vascular scaffold in an anomalous coronary artery. Int J Cardiol 223:239-41.
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).